PRESS RELEASE


  • Siena, March 1st, 2011
    Philochem AG, the research unit of Philogen S.p.A., announces that it has entered a collaborative agreement with Pfizer Inc. in the field of cancer target discovery.
  • 2010 - Philochem and Merck Serono Enter Into Research Agreement In Fertility.
    Philochem AG, Switzerland, the research unit of Philogen S.p.A., Italy and Merck Serono, the pharmaceutical division of Merck KGaA, Darmstadt, Germany, today announced a strategic agreement. Under the terms of the agreement, Philochem will supply specific recombinant antibodies to Merck Serono, to be used in the search for molecular biomarkers of oocyte and embryo quality. Further terms of the agreement are not disclosed. Once validated, molecular biomarkers can be used for the development of predictive or diagnostic tests that can help physicians assess objectively oocyte and embryo quality.
  • 2007 - Philochem together with ETH Zurich have won a 3 years “Discovery Grant” from KTI/CTI, the swiss innovation and promotion agency.
  • 2007 - Philochem AG and Cambridge Antibody Technology (CAT) signed a technology evaluation agreement for Philochem to apply its proprietary DNA-encoded libraries to the discovery of low molecular weight compounds against three undisclosed targets of pharmaceutical interest.